Medios AG MEDIOS ORD SHS/  DE000A1MMCC8  /

LSE International Off-book
2024-11-15  12:29:09 PM Chg. -0.12 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
14.58EUR -0.82% 130
Turnover: 1,895.40
-Bid Size: - -Ask Size: - 345.66 mill.EUR - 18.38

Business description

Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios Manufaktur GmbH, has positioned itself in the specialty pharma segment as the go-to source for expertise and solutions. It brings together individual market players in a network of cooperating partners. Specialty pharmaceutical drugs are medications for patients with rare and/or chronic illnesses (for example, cancer, autoimmune diseases, and infectious diseases) that require lengthy and expensive treatment. Medios AG buys, sells and manages investments of innovative companies. The company aims to establish a strategic investment portfolio and to support its governance.
 

Management board & Supervisory board

CEO
Matthias Gärtner
Management board
Falk Neukirch, Christoph Prußeit, Mi-Young Miehler, Constantijn van Rietschoten
Supervisory board
Dr. Yann Samson, Joachim Messner, Dr. Anke Nestler, Klaus Buß
 

Company data

Name: Medios AG
Address: Friedrichstraße 113a,D-10117 Berlin
Phone: +49 30 232 566 800
Fax: +49 30 232 566 800
E-mail: info@medios.ag
Internet: www.medios.ag
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 58.50%
IPO date: 1999-07-15

Investor relations

Name: Claudia Nickolaus
IR phone: +49 30 232 566 800
IR Fax: -
IR e-mail: ir@medios.ag

Main Shareholders

FreeFloat
 
58.50%
Martin Hesse
 
19.70%
Luxempart Invest S.á.r.I.
 
15.10%
Bencis Capital Partners B.V.
 
6.70%